Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast Cancer
Dr Adam M Brufsky from UPMC Hillman Cancer Center in Pittsburgh summarizes the history of and modern advances in treating localized HER2-positive breast cancers, including strategies for monitoring and managing treatment-related toxicities. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayLocHER2PosBC24).
